Kura Oncology (NASDAQ:KURA) Upgraded at StockNews.com

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a research note published on Friday.

Several other equities research analysts have also recently commented on KURA. TD Cowen restated a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. UBS Group cut their target price on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday. BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Finally, Scotiabank cut their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Trading Down 2.2 %

NASDAQ:KURA opened at $7.53 on Friday. Kura Oncology has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock has a market capitalization of $608.09 million, a PE ratio of -3.19 and a beta of 0.85. The business’s 50-day simple moving average is $8.00 and its 200-day simple moving average is $13.29.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. Sell-side analysts expect that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock valued at $92,307 in the last ninety days. 5.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Kura Oncology

Several institutional investors and hedge funds have recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Kura Oncology by 35.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock worth $579,000 after purchasing an additional 7,722 shares in the last quarter. Intech Investment Management LLC acquired a new position in Kura Oncology in the 3rd quarter worth about $298,000. Charles Schwab Investment Management Inc. increased its holdings in Kura Oncology by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock worth $12,212,000 after purchasing an additional 14,106 shares in the last quarter. Algert Global LLC increased its holdings in Kura Oncology by 4.4% in the 3rd quarter. Algert Global LLC now owns 272,276 shares of the company’s stock worth $5,320,000 after purchasing an additional 11,493 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Kura Oncology in the 3rd quarter worth about $596,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.